Replies to post #223123 on Biotech Values

[semi_infinite]

JNCE 2015 SITC slides

https://www.sitcancer.org/HigherLogic/System/DownloadDocumentFile.ashx?DocumentFileKey=61eb1765-37fd-845a-f228-8d92af893886&forceDialog=1

[poorgradstudent]

JNCE:

From the reading I did, I *could* make a case for CTLA-4. However, it appears that CTLA-4 antagonism upregulates ICOS. So if a cell needs to be responsive to CTLA-4 blockade to upregulate ICOS, then what strong need is there for JNCE's drug? It becomes a small, incremental addition to the response rather than an independent driver for a response.

Meh.